Phase I trial of escalating-dose cisplatin with 5-fluorouracil and concurrent radiotherapy in Chinese patients with esophageal cancer

Acta Medica Okayama

Volumn 62, Issue 1, 2008, Pages 37-44

  Lin, Qiang ^a,c   Gao, Xian Shu ^a,b   Qiao, Xue Ying ^a   Zhou, Zhi Guo ^a   Zhang, Ping ^a   Chen, Kun ^c   Zhao, Yan Nan ^c   Asaumi, Junichi ^d  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b PEKING UNIVERSITY FIRST HOSPITAL   (China)

^c North China Petroleum Administration Bureau   (China)

^d OKAYAMA UNIVERSITY   (Japan)

Author keywords

5 fluorouracil; Cisplatin; Concurrent chemoradiotherapy; Dose escalation; Esophageal neoplasm

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; CISPLATIN; FLUOROURACIL;

ADULT; AGED; ARTICLE; ASIAN; CLINICAL TRIAL; DOSE RESPONSE; ESOPHAGUS TUMOR; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PHASE 1 CLINICAL TRIAL; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; ESOPHAGEAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED;

EID: 41549114727     PISSN: 0386300X     EISSN: 0386300X     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics 2002. CA Cancer J Clin (2005) 55: 74-108.
2. Enzinger PC and Mayer RJ: Esophageal cancer. N Engl J Med (2003) 349: 2241-2252.
3. Brenner B, Ilson DH and Minsky BD: Treatment of localized esophageal cancer. Semin Oncol (2004) 31: 554-565.
4. Herskovic A, Martz K, al-Sarraf M, Leichman L, Brindle J, Vaitkevicius V, Cooper J, Byhardt R, Davis L and Emami B: Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med (1992) 326: 1593-1598.
5. Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson JA Jr, Al-Sarraf M, Byhardt R, Russell AH, Beitler JJ, Spencer S, Asbell SO, Graham MV and Leichman LL: Chemoradiotherapy of Locally Advanced Esophageal Cancer. Long-term Follow-up of a Prospective Randomized Trial (RTOG 85-01). JAMA (1999) 281: 1623-1627.
6. Gao XS, Qiao XY, Yang XR, Asaumi J, Zhou ZG, Wang YD, Zhou DA, Wan J, Kuroda M, Kishi K, Kawasaki S and Hiraki Y: Late course accelerated hyperfractionation radiotherapy concomitant with cisplatin in patients with esophageal carcinoma. Oncol Rep (2002) 9: 767-772.
7. Ren BZ, Shan CP, Han L and Zhu PJ: Late accelerated hyper fractionated and three dimensional conformal radiotherapy plus concurrent chemotherapy on stage III esophageal carcinoma. Chin J Radiat Oncol (2004) 13: 265-263.
8. Zhao KL, Shi XH, Jiang GL, Yao WQ, Guo XM, Wu GD and Zhu LX: Late course accelerated hyperfractionated radiotherapy plus concurrent chemotherapy for squamous cell carcinoma of the esophagus: a phase III randomized study. Int J Radiat Oncol Biol Phys (2005) 62: 1014-1020.
9. Zhang H, Yu MG, Qian RY and Fan LH: Evaluation of late course accelerated hyperfractionated radiotherapy plus concurrent chemotherapy for esophageal carcinoma. Chin J Radiat Oncol (2006) 15: 89-92.
10. Law S and Wong J: Current status of esophageal cancer treatment in Asia. Esophagus (2004) 1: 169-176.
11. Shi XH, Yao W and Liu T: Late course accelerated fractionation in radiotherapy of esophageal carcinoma. Radiother Oncol (1999) 51: 21-26.
12. Han C, Yang XR, Gao XS, Zhou DA and Wan J: Late course accelerated hyperfractionated radiotherapy for esophageal carcinoma [Abstract]. Chin J Radiat Onco (1999) 18: 192.
13. Duan YJ, Tang WC, Han XL, Wu DP and Qi LX: Late course accelerated hyperfractionation combined with synchronizing chemotherapy for esophageal carcinoma. J Fourth Mil Med Univ (2003) 24: 21-23.
14. Zhu SC, Li R, Li J, Qiu R, Han C and Wan J: Preliminary study of clinical staging of moderately advanced and advanced thoracic esophageal carcinomatreated by non-surgical methods. Chin J Radiat Oncol (2004) 13: 189-192.
15. Wan J, Gao SZ and Guo BZ: Study of radiation dosage in esophageal carcinoma. Chin Med J (Engl) (1992) 105: 132-134.
16. Minsky BD, Pajak TF, Ginsberg RJ, Pisansky TM, Martenson J, Komaki R, Okawara G, Rosenthal SA and Kelsen DP: INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol (2002) 20: 1167-1174.
17. Trotti A, Byhardt R, Stetz J, Gwede C, Corn B, Fu K, Gunderson L, McCormick B, Morrisintegral M, Rich T, Shipley W and Curran W: Common toxicity criteria: version 2.0.an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys (2000) 47: 13-47.
18. Cox JD, Stetz J and Pajak TF: Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys (1995) 31: 1341-1346.
19. Kok TC: Chemotherapy in oesophageal cancer. Cancer Treat Rev (1997) 23: 65-85.
20. Brenner B, Ilson DH, Minsky BD, Bains MS, Tong W, Gonen M and Kelsen DP: Phase I trial of combined-modality therapy for localized esophageal cancer: escalating doses of continuous-infusion paclitaxel with cisplatin and concurrent radiation therapy. J Clin Oncol (2004) 22: 45-52.
21. Maurel J, Cervantes A, Conill C, Salazar R, Martin-Richard M, Pera M, Manzano H, Chirivella I, Gallego R and Marfa X: Phase I trial of oxaliplatin in combination with cisplatin, protacted-infusion fluorouracil, and radiotherapy in advanced esophageal and gastroesophageal carcinoma. Int J Radiat Oncol Biol Phys (2005) 62: 91-96.
22. Ilson DH, Bains M, Kelsen DP, O'Reilly E, Karpeh M, Coit D, Rusch V, Gonen M, Wilson K and Minsky BD: Phase I trial of escalating-dose irinotecan given weekly with cisplatin and concurrent radiotherapy in locally advanced esophageal cancer. J Clin Oncol (2003) 21: 2926-2932.
23. Ishida K, Ando N, Yamamoto S, Ide H and Shinoda M: Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell career of the esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial (JCOG9516). Jpn J Clin Oncol (2004) 34: 615-619.
24. Toita T, Ogawa K, Adachi G, Kakinohana Y, Nishikuramori Y, Iraha S, Utsunomiya T and Murayama S: Concurrent chemoradiotherapy for squamous cell carcinoma of thoracic esophagus: feasibility and outcome of large regional field and high-dose external beam boost irradiation. Jpn J Clin Oncol (2001) 31: 375-381.
25. Lee JL, Kim SB, Jung HY, Park SI, Kim DK, Kim JH, Song HY, Kim WK, Lee JS and Min YI: Efficacy of neoadjuvant chemoradiotherapy in resectable esophageal squamous cell carcinoma-a single institutional study. Acta Oncol (2003) 42: 207-217.